Celularity

Celularity has raised $290M and completed post-IPO capital transactions in 2025. Founded in 2016, Celularity develops placenta-derived allogeneic cell therapies targeting oncology, infectious, and degenerative diseases. Lead candidates include placental NK and stromal cell programs such as CYNK001. Funding has supported clinical trials, manufacturing scale-up, and translational research. Backing from Celgene and United Therapeutics enabled the development of cell banks, regulatory filings, and early human studies to demonstrate safety and efficacy. Celularity’s platform advances scalable, off-the-shelf cell therapeutics with the goal of broad clinical application.